{
    "id": 711,
    "name": "refractory hairy cell leukemia",
    "source": "DOID",
    "definition": "A refractory hematologic cancer that is a mature B cell cancer that does not yield readily to treatment. [url:http\\://en.wikipedia.org/wiki/Hairy_cell_leukemia, url:http\\://www.medterms.com/script/main/art.asp?articlekey=5274]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:711",
    "evidence": [
        {
            "id": 15709,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a single patient with hairy cell leukemia who relapsed after initial response to Zelboraf (vemurafenib) was found to have acquired multiple clones with Mek/Erk activating mutations, of which the MAP2K1 K57T clone became dominant, and demonstrated a sustained response greater than 12 months to combined Zelboraf (vemurafenib) and Cotellic (cobimetinib) treatment (PMID: 30341394).",
            "molecularProfile": {
                "id": 31172,
                "profileName": "BRAF V600E MAP2K1 K57T"
            },
            "therapy": {
                "id": 1657,
                "therapyName": "Cobimetinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 711,
                "name": "refractory hairy cell leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 13685,
                    "pubMedId": 30341394,
                    "title": "Targeting MEK in vemurafenib-resistant hairy cell leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30341394"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}